ExlService Holdings, Inc. (EXLS) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. ExlService Holdings, Inc. is a global data and artificial intelligence (AI) company providing services to industries including insurance, healthcare, life sciences, banking, and capital markets. In Q1 2025, the company realigned its reporting structure into four Industry Market Units (IMUs): Insurance; Healthcare and Life Sciences; Banking, Capital Markets and Diversified Industries; and International Growth Markets.
Key Financial Metrics
| Metric (in millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenues, net | $514.5 | $448.4 | $1,015.5 | $884.9 |
| Gross Profit | $194.2 | $166.3 | $387.5 | $329.4 |
| Gross Margin | 37.7% | 37.1% | 38.2% | 37.2% |
| Income from Operations | $81.2 | $61.5 | $159.5 | $123.0 |
| Net Income | $66.1 | $45.8 | $132.6 | $94.6 |
| Diluted EPS | $0.40 | $0.28 | $0.81 | $0.57 |
| Cash from Operations (YTD) | $112.6 | $53.0 | - | - |
| Total Debt (Net of issuance costs) | $260.0 | - | - | - |
| Cash & Short-term Investments | $353.3 | - | - | - |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2025 revenue increased 14.7% year-over-year (YoY), driven by expansion in all reportable segments. The Healthcare and Life Sciences segment saw the highest growth at 22.0%, aided by the August 2024 acquisition of ITI Data.
- Profitability: Net income surged 44.1% YoY to $66.1 million. Operating income grew 32.0% to $81.2 million, supported by a 60 basis point expansion in gross margin.
- Cost Management: Cost of revenues increased 13.5% YoY, primarily due to higher employee-related costs (headcount and wage inflation) and technology costs. SG&A expenses rose 7.7% YoY, partially offset by the absence of one-time restructuring costs incurred in Q2 2024.
- Cash Flow: Net cash provided by operating activities for the six months ended June 30, 2025, more than doubled to $112.6 million compared to $53.0 million in the prior year period, reflecting higher cash earnings and improved working capital management.
- Debt Reduction: Total borrowings decreased to $260.0 million as of June 30, 2025, from $288.5 million at year-end 2024, due to net repayments of borrowings.
Guidance, Outlook, and Risks
- Capital Expenditures: The company expects total capital expenditures for fiscal 2025 to be between $50.0 million and $55.0 million, focused on facilities, infrastructure, and digital technologies.
- Share Repurchases: On July 29, 2025, the company entered into an Accelerated Share Repurchase (ASR) agreement for $125 million under its $500 million 2024 Repurchase Program. Approximately $273.1 million remains available under the program as of June 30, 2025.
- Tax Legislation: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) signed on July 4, 2025, which extends certain provisions of the 2017 Tax Cuts and Jobs Act.
- Risks and Contingencies:
- Tax Disputes: The company faces transfer pricing and VAT disputes with Indian tax authorities. Aggregate demands net of advance payments were $50.2 million as of June 30, 2025. The company believes its positions will be sustained and has not accrued liabilities.
- Client Concentration: The top ten clients accounted for 33.5% of Q2 2025 revenues. The loss of any top ten client could have a material adverse effect.
- AI and Cybersecurity: Risks include the successful integration of AI technologies, cybersecurity incidents, and data breaches.
Investor Verification Checklist
- Segment Realignment Impact: Verify how the Q1 2025 restructuring into IMUs affects future comparability of segment performance.
- Acquisition Integration: Assess the contribution of the ITI Data acquisition to the Healthcare and Life Sciences segment growth and associated integration costs.
- Indian Tax Exposure: Monitor the status of the $50.2 million in tax demands from Indian authorities and the sufficiency of bank guarantees provided.
- Wage Inflation: Track the impact of rising employee costs on gross margins, particularly in the Insurance and Healthcare segments.
- Share Repurchase Execution: Confirm the settlement details and share count impact of the $125 million ASR agreement entered into in July 2025.